NanoViricides, Inc. (NYSE American: NNVC) is awaiting regulatory approval to initiate a Phase II clinical trial of its NV-387 Oral Gummies for the treatment of Bundibugyo ebolavirus in the Democratic Republic of the Congo. The company announced that it has submitted an application to the local regulatory agency and has secured financing to support the study, which targets the ongoing Ebola outbreak.
According to the company, NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical testing, to its knowledge. The broad-spectrum antiviral mechanism could offer advantages over infusion-based therapies in resource-limited outbreak settings, where access to intravenous treatments is often challenging. NanoViricides noted that sufficient quantities of the drug are already in the DRC to support the planned study, pending regulatory approval.
The Bundibugyo ebolavirus strain has no approved treatment or vaccine, making the potential trial particularly significant. If approved, the study could provide a much-needed oral therapeutic option for patients in affected regions. The company believes NV-387's mechanism of action, which targets viral entry and replication, may be effective against multiple viruses, including Ebola.
NanoViricides is a clinical-stage company specializing in nanomaterial-based antiviral therapies. Its lead drug candidate, NV-387, is also being developed for respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, and other viral infections, including mpox, smallpox, and measles. The company's technology is based on intellectual property licensed from TheraCour Pharma, Inc.
The planned Ebola trial represents a critical step for NanoViricides as it seeks to demonstrate the efficacy of its oral formulation in a real-world outbreak. The company faces typical drug development risks, including the lengthy and capital-intensive nature of clinical trials, and there is no assurance that NV-387 will prove safe and effective in humans.
For more information, visit the company's newsroom at https://ibn.fm/NNVC.
